Use of CD36 to identify cancer subjects for treatment
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12372529-B2
Publication Date
2025-07-29
Expiration Date
Abstract
Provided herein are methods for identifying a subject with cancer for treatment with a Psap peptides. The subject is identified based on a level of CD36. Also provided herein are compositions and methods for treatment of a subject with cancer based on a level of CD36.
Core Innovation
The invention relates to determining responsiveness to treatment with a Psap peptide in a subject having cancer by evaluating the level of CD36 in a sample obtained from the subject. Elevated levels of CD36 in the sample, compared to a control level, indicate that the subject is responsive to, or likely to be responsive to, treatment with a Psap peptide. The described approach uses an assay to determine the level of CD36.
The invention further ties this responsiveness determination to the administration of an effective amount of a Psap peptide to treat the cancer in subjects identified as responsive or likely to be responsive. The Psap peptide is selected from the group consisting of CDWLPK (SEQ ID NO:1), DWLPK (SEQ ID NO:2), and DWLP (SEQ ID NO:3). The described framework supports evaluating CD36 status as a basis for selecting subjects for Psap peptide treatment.
The disclosed content explains that elevated CD36 levels in tumor cells indicate responsiveness to Psap peptides, and it describes diagnostic and treatment-selection methods based on measuring CD36 in a subject sample. The disclosed material also describes proposed mechanism linking Psap-elicited Tsp-1 to direct tumor-cell effects via CD36, and it supports the concept with examples showing that Psap peptide effects correlate with high versus low CD36 expression across multiple cancer types.
Claims Coverage
The provided partial content includes one independent claim with three main inventive aspects: determining responsiveness by measuring CD36 in a cancer sample relative to a control level, using an assay to determine the CD36 level, and administering an effective amount of a specified Psap peptide to treat the cancer based on that determination.
CD36 level indicates responsiveness to Psap peptide
Determining a level of CD36 in a sample obtained from a subject having cancer, wherein an elevated level of CD36 in the sample compared to a control level indicates that the subject is responsive to or likely to be responsive to treatment with a Psap peptide.
Assaying CD36 in the subject sample
Determining the level of CD36 in the sample by performing an assay.
Administering a specified Psap peptide based on CD36 elevation
Administering to the subject identified as responsive to or likely to be responsive to treatment with a Psap peptide an effective amount of a Psap peptide to treat the cancer, wherein the Psap peptide is selected from the group consisting of CDWLPK (SEQ ID NO: 1), DWLPK (SEQ ID NO: 2), and DWLP (SEQ ID NO: 3).
Across the independent claim, responsiveness is evaluated by CD36 measurement versus a control level, the measurement is performed via an assay, and treatment is administered using an effective amount of a Psap peptide limited to CDWLPK (SEQ ID NO:1), DWLPK (SEQ ID NO:2), or DWLP (SEQ ID NO:3) for subjects identified as responsive or likely responsive.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?